Sargent Bickham Lagudis LLC Kaleido Biosciences, Inc. Call Options Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KLDO
# of Institutions
2Shares Held
2.65KCall Options Held
0Put Options Held
0About Kaleido Biosciences, Inc.
- Ticker KLDO
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,622,600
- Description
- Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...